Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects

BACKGROUND: Imrecoxib is a novel and moderately selective cyclooxygenase-2 inhibitor with properties of anti-inflammation and alleviating pain, which is widely applied in osteoarthritis patients. The pharmacokinetic data supporting imrecoxib’s rational use in elderly population are not available. PU...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ling, Shen, Qi, Hu, Chao, Wang, Ying, Zhu, Xiaohong, Shu, Shiqing, Luo, Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653025/
https://www.ncbi.nlm.nih.gov/pubmed/36388081
http://dx.doi.org/10.2147/DDDT.S387508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653025/
https://www.ncbi.nlm.nih.gov/pubmed/36388081
http://dx.doi.org/10.2147/DDDT.S387508

Ejemplares similares